Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2010. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of insider trading activity and does not contain financial performance data.
Material Changes
The material change disclosed is a transaction involving Dr. M. Slaoui, a Person Discharging Managerial Responsibility. Due to the partial vesting of a Performance Share Plan award made in 2007 to Dr. Slaoui's connected person, 275 American Depositary Shares (ADSs) vested. The balance of the award lapsed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: February 24, 2010.
- Individual Involved: Dr. M. Slaoui (via a connected person).
- Transaction Type: Vesting of 275 ADSs from a 2007 Performance Share Plan; remainder of award lapsed.
- Financial Impact: No financial metrics are disclosed in this specific filing.